Tumor cell-derived lactic acid inhibits the interaction of PD-L1 protein and PD-L1 antibody in the PD-L1/PD-1 blockade therapy-resistant tumor
Oh, W.; Kim, A. M. J.; Dhawan, D.; Knapp, D. W.; Lim, S.-O.
Show abstract
Immune checkpoint blockade therapy targeting the PD-1/PD-L1 axis has shown remarkable clinical impact in multiple cancer types. Nontheless, despite the recent success of PD-1/PD-L1 blockade therapy, such response rates in cancer patients have been limited to tumors encompassing specific tumor microenvironment characteristics. The altered metabolic activity of cancer cells shapes the anti-tumor immune response by affecting the activity of immune cells. However, it remains mostly unknown how the altered metabolic activity of cancer cells impacts their resistance to PD-1/PD-L1 blockade therapy. Here we found that tumor cell-derived lactic acid renders the immunosuppressive tumor microenvironment in the PD-1/PD-L1 blockade-resistant tumors by inhibiting the interaction between the PD-L1 protein and anti-PD-L1 antibody. Furthermore, we showed that the combination therapy of targeting PD-L1 with our PD-L1 antibody-drug conjugate (PD-L1-ADC) and reducing lactic acid with the MCT-1 inhibitor, AZD3965, can effectively treat the PD-1/PD-L1 blockade resistant tumors. The findings in this study provide a new mechanism of how lactic acid induces an immunosuppressive environment and suggest a potential combination treatment to overcome the PD-1/PD-L1 blockade therapy resistance.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 96%
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 96%
- DUSP11 is an intracellular innate immune checkpoint in lung adenocarcinoma 95%
Similar papers in this journal
- IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors 95%
- Rapid generation of CD19 CAR-T Cells by minicircle DNA enables anti-tumor activity and prevents fatal CAR-B leukemia 94%
- ECD co-operates with ERBB2 to promote tumorigenesis through upregulation of unfolded protein response and glycolysis 94%
Similar papers in this journal
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 97%
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy 96%
- Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction 96%
Similar papers in this journal
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 95%
- Antibody Targeting of B7-H4 Enhances the Immune Response in Urothelial Carcinoma 95%
- Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.